Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial

Cardiovascular Diabetology(2025)10.1186/s12933-025-02875-6Source: DataRank Database

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial is a research paper published in Cardiovascular Diabetology (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access0 citations

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04350593

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.00)OA: goldTopics (40)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (23)

Remo H.M. Furtado,Russell Esterline,Jan Oscarsson ORCID,Samvel B. Gasparyan ORCID,Gary G. Koch

Live enrichment

PubMed:40739638 PMC:PMC12312311 OpenAlex:https://openalex.org/W4412744885

AstraZeneca Pharmaceuticals LP

Grant: ESR-20-20653

FWCI

0.00

Citation Percentile

0.2%

goldLicense: cc-by-nc-nd

journalhttps://cardiab.biomedcentral.com/counter/pdf/10.1186/s12933-025-02875-6

publisherhttps://cardiab.biomedcentral.com/counter/pdf/10.1186/s12933-025-02875-6

publisherhttps://link.springer.com/content/pdf/10.1186/s12933-025-02875-6.pdf

publisherhttps://link.springer.com/article/10.1186/s12933-025-02875-6/fulltext.html

journalhttps://doi.org/10.1186/s12933-025-02875-6

Fields of Study

Diabetes Treatment and ManagementPancreatic function and diabetesHyperglycemia and glycemic control in critically ill and hospitalized patients

MeSH Terms

Sodium-Glucose Transporter 2 InhibitorsCOVID-19SARS-CoV-2COVID-19 Drug TreatmentAgedBenzhydryl CompoundsBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucosidesHospitalizationHumansMaleMiddle AgedRisk FactorsBiomarkersTreatment Outcome

Keywords

MedicineDapagliflozinCoronavirus disease 2019 (COVID-19)Randomized controlled trialType 2 diabetesAngiologyDiabetes mellitus2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineIntensive care medicineVirologyEndocrinologyOutbreakDiseaseSafetyAcute IllnessSodiuM-glucose Co-transporter-2 Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial

FAIR Checklist

Authors (23)

Funding (1 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)